Section 7: Post Congress additions最新文献

{"title":"4CPS-242 Human immunodeficiency virus pre-exposure prophylaxis: analysis, follow-up and pandemic effect","authors":"C. Vila Gallego, M. Alvarez Lavin, M. Alonso Díez, M. Vara Urruchua, A. Revuelta Amallo, M. Inclan Conde, N. Pardo Santos, A. Aguirrezábal Arredondo, J. Muñoz Sanchez","doi":"10.1136/ejhpharm-2022-eahp.409","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.409","url":null,"abstract":"Background and importanceIn 2019, the National Health System (NHS) approved funding for the indication of pre-exposure prophylaxis (PreP) as an strategy to prevent human immunodeficiency virus (HIV) infection in high-risk populations. The hospital pharmacy (HP), together with the Sexually Transmitted Infection (STI) centre, has created an interdisciplinary circuit where these individuals are closely monitored.Aim and objectivesTo characterise the user population of the HIV PrEP programme and assess the adequacy of the circuit, as well as the impact of the SARS-CoV-2 pandemic.Material and methodsRetrospective observational study of the PrEP programme from November 2019 to April 2021 carried out in the provincial STI treatment centre and the HP.The following were assessed: compliance with inclusion criteria, adherence to treatment and causes of discontinuation, toxicity, acquisition of STIs and interactions. Also variations during confinement and degree of involvement by COVID.Results169 males, aged 39.6±10.0 (range 19–64) years, all met at least one inclusion criterion in the last year: 75.7% (n=128) men who have sex with men (MSM) with more than 10 different sexual partners, 71.6% (n=121) MSM anal sex without condoms, 17.1% (n=29) MSM drug use, 10.7% (n=18) MSM with multiple PreP, 74.0% (n=125) MSM with at least one STI and one engaged in prostitution.30 clients discontinued medication: 33.3% (n=10) stopped risky practices, 20.0% (n=6) digestive toxicity (main adverse effect), 3.3% (n=1) poor adherence, 16.7% (n=5) client choice and 26.7% (n=8) drop out of follow-up. Mean adherence was 94.5±11.4.No patients acquired HIV during treatment, but other STIs were found (several users reported reduced of condom use): 36.7% (n=11) Treponema pallidum, 56.7% (n=17) Chlamydia trachomatis, 63.3% (n=19) Neisseria gonorrhoeae and 36.7% (n=11) Mycoplasma genitalum.This was a young population that does a lot of physical exercise and after the clinical interview it was discovered they were abusing protein shakes and anabolic steroids, therefore they were warned about it.During the confinement, 41 users were in treatment. Of the 37 who continued, 4 suffered from COVID.Conclusion and relevanceThe programme meets the requirements of the NHS, with high adherence to treatment and a good safety profile.Patients continued with PreP during confinement and there was a significant number affected by COVID.Clinical pharmaceutical follow-up has allowed preventive and corrective interventions, but more emphasis should be placed on the use of condoms and avoiding anabolic steroids given the possible renal repercussions.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127106699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-111 Pharmaceutical intervention: avoiding interactions between antiretrovirals and vitamin supplements/antacids","authors":"M. Gutiérrez Lorenzo, P. Ciudad Gutiérrez, M. F. Fernández Gonzalez, P. del Valle Moreno","doi":"10.1136/ejhpharm-2022-eahp.424","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.424","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"135 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122978757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-217 Clinical, economic and organisational impact of pharmacists’ interventions in oncological care patients","authors":"MM Parera Pascual, G. González Morcillo, M. Bello Crespo, M. Nigorra Caro, L. Pérez de Amezaga Tomás, A. Brady Garcia, MA Crespí Cifre, M. Vilanova Boltó","doi":"10.1136/ejhpharm-2022-eahp.406","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.406","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121850305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-264 Analysis of medical treatment, risk factors and recurrence ofClostridioides difficilenosocomial diarrhoea","authors":"JI Bretones Pedrinaci, A. Martos Rosa, M. Herrera Expósito, J. Urda Romacho, M. C. Castro Vida","doi":"10.1136/ejhpharm-2022-eahp.414","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.414","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121986849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-002 Adverse events reported after administration of BNT162B2 and mRNA-1273 COVID-19 vaccines among healthcare workers","authors":"M. Valera Rubio, MI Sierra-Torres, R. Castillejo-García, J. Cordero-Ramos, JF Álvarez-Zarallo, M. Calleja‐Hernández","doi":"10.1136/ejhpharm-2022-eahp.417","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.417","url":null,"abstract":"Background and importanceSince December 2019, the world has faced a new disease known as COVID-19. On 11 March 2020, the World Health Organization officially declared the COVID-19 pandemic. Given the health emergency, vaccine development progressed rapidly, but with limited safety data under real-world conditions.Aim and objectivesTo describe and compare the incidence of adverse events with the BNT162b2 and mRNA-1273 COVID-19 vaccines, taking into account the number of doses and subjects previously positive for SARS-CoV-2 infection.Material and methodsA retrospective observational study was conducted in a tertiary hospital between March and April 2021. Data were collected through a questionnaire sent by email to hospital staff. Demographics and data regarding the occurrence of adverse events were collected, indicating which vaccine was administered. Statistical analysis was performed using SPSS software. Groups were compared using the Chi-square test and Fisher’s exact test when necessary.Results1249 respondents completed the survey (25% of all hospital staff);52% (650) received BNT162b2 vaccine and 48% (599) mRNA-1273. 14 402 adverse reactions were recorded. 6896 were local: 3939 were with mRNA-1273 and 2957 with BNT162b2 (6.6 vs 4.4 reactions per patient);and 7506 were systemic: 4460 with mRNA-1273 and 3046 with BNT162b2 (7.4 vs 4.7 per patient). The occurrence of local reactions was 95.8% after the first dose/89.1% after the second dose with mRNA-1273 versus 89.7%/82.5% with BNT162b2. For systemic reactions, this proportion was 64.3%/93.3% versu 46.8%/73.2% (p value<0.05).In terms of severity, 379 patients (63.3%) with mRNA-1273 confirmed a severe reaction versus 222 (34.2%) with BNT162b2 and 60 patients (10%) with mRNA-1273 confirmed an urgent reaction versus 33 (5.1%) with BNT162b2 (p value<0.001). For both vaccines, there was no difference in the occurrence of local or systemic reactions between patients seropositive and seronegative for SARS-CoV-2.Conclusion and relevanceThe results are consistent with the limited data available to date, confirming that although these are not particularly serious adverse effects, they do occur in a large majority of vaccinated persons and in greater numbers after administration of the mRNA-1273 vaccine. The Hospital Pharmacy Service is a key agent in pharmacovigilance within the healthcare system and must be aware of the safety profile of new drugs. This study is an essential tool to detect and prevent adverse events.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114616841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-062 Rituximab pharmacokinetics characterisation in plasma and urine in a patient with nephotic syndrome","authors":"M. Larrosa García, I. Agraz Pamplona, RP Bury Macias, M. Sanz Martínez, J. Perurena Prieto, M. Martínez Gallo, M. HERNANDEZ GONZALEZ, D. Anguita Domingo, J. Montoro Ronsano, M. G. Gorgas Torner","doi":"10.1136/ejhpharm-2022-eahp.387","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.387","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121449015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-005 Analysis of the use of monoclonal antibodies for the treatment of COVID-19 in clinical practice: a weapon in the fight against the pandemic, alongside vaccination","authors":"G. Pellegrino, E. Grande, E. Bersia, E. Bastonero, M. Rebora, C. Fruttero","doi":"10.1136/ejhpharm-2022-eahp.418","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.418","url":null,"abstract":"Background and importanceVaccines are emerging as a fundamental tool in the prevention of COVID-19 disease but are not decisive in treating it, once contracted. Anti COVID-19 monoclonal antibodies (MAb) define a valuable and parallel resource for the treatment of coronavirus infection so it is useful to monitor the usage data, adverse reactions (ADRs) and percentage of hospitalisations after treatment.Aim and objectivesPurpose of the work was to provide data on safety and efficacy of anti-COVID MAb in consideration of their use in current clinical practice.Material and methodsUsing a home-made database, the pharmacy extrapolated and reprocessed the data relating to the reports of patient recruitment by local and hospital clinicians, the number of patients who were treated, the specific therapies administered (bamlanivimab, bamlanivimab/etesevimab or casirivimab/imdevimab) and ADRs reported by doctors.In parallel, the infectious diseases department monitored the percentage of patients who still needed hospitalisation after the infusion of MAb.ResultsMost of the recruitment reports were received from general doctors (82% vs 18% from hospitals) and, from March 2021 to September 2021, 104 patients were treated: 48 patients (46.2%) with bamlanivimab/etesevimab, 55 (52.9%) with casirivimab/imdevimab and 1 (0.9%) with bamlanivimab. 67% of patients were not vaccinated while 33% received at least one dose of vaccine (58%: first dose;42%: two doses). The main comorbidity found was the cardiological/cerebral/vascular type.Following outpatient dosing, 2 ADRs have been reported: an emetic episode after bamlanivimab infusion and a subacute antero-septal myocardial infarction with acute pulmonary oedema occurring within hours after administration of casirivimab/imdevimab and in the presence of a septic event of bacterial origin. 9% of patients treated with anti-COVID-19 MAb still required hospitalisation due to COVID-19;the other patients recovered completely.Conclusion and relevanceTogether with the home care protocol and vaccines, MAb constitute a valid weapon in the early phase of COVID-19 disease. It is an important opportunity because it allows the virus to be faced in an active way, without waiting for the worsening of the patient’s clinical condition, and with a synergistic approach of hospital and territory that join forces against this great infectious disease challenge.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130248975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-024 Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non-small-cell lung cancer (LA-NSCLC)","authors":"Z. Rodríguez Fernández, B. Távara Silva, B. Matilla Fernández, X. Casás Fernández, A. Vélez Blanco, JC Sáez Hortelano, C. De Castro Avedillo, R. Varela Fernández, A. Martín Sanz, C. Guindel Jiménez, C. Arenós Monzó","doi":"10.1136/ejhpharm-2022-eahp.419","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.419","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128951234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-245 Inappropriate antibiotic dosage adjustments in patients with renal impairment: a cross-sectional analysis","authors":"A. Aguado Paredes, M. Valera Rubio, L. Moñino-Dominguez","doi":"10.1136/ejhpharm-2022-eahp.410","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.410","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"406 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115236926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-181 Clinical-pharmaceutical medication counselling for pneumological patients in outpatient and inpatient areas","authors":"T. Grillitsch, IM Lagoja","doi":"10.1136/ejhpharm-2022-eahp.402","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.402","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116258638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}